Neisseria meningitidis capsular polysaccharide antigens conjugated to tetanus toxoid carrier (Men-TT)

Neisseria meningitidis capsular polysaccharide antigens conjugated to tetanus toxoid carrier represent a critical immunogenic complex used in vaccines to prevent invasive meningococcal disease. Neisseria meningitidis is a major cause of bacterial meningitis and sepsis, characterized by a polysaccharide capsule that allows the pathogen to evade host immune detection (WHO, 2023). While pure polysaccharide vaccines are poorly immunogenic in children under two years of age and do not induce immunological memory, the covalent attachment to a tetanus toxoid carrier protein recruits T-cell involvement (StatPearls, 2023). This conjugation enables the induction of high-affinity IgG antibodies and the establishment of long-lived memory B cells, providing durable protection across all age groups (EMA, 2023). The target typically encompasses serogroups A, C, W-135, and Y, which are responsible for the majority of meningococcal outbreaks globally (CDC, 2022).

Other names

Meningococcal polysaccharide-tetanus toxoid conjugateMenACWY-TTMenC-TTMeningococcal conjugate vaccineNeisseria meningitidis group A, C, W-135, and Y capsular polysaccharide tetanus toxoid conjugate

The vaccine component acts by introducing bacterial capsular polysaccharides covalently linked to a tetanus toxoid protein carrier. This conjugation converts the T-cell independent polysaccharide into a T-cell dependent antigen; the carrier protein is processed by antigen-presenting cells and presented via MHC class II to T-helper cells, which then provide the necessary signals to B cells for isotype switching, affinity maturation, and the development of long-term memory B cells (Pollard et al., 2009; CDC, 2022).